Prise en charge des métastases osseuses du cancer de la prostate. À propos d'un cas

25 mars 2010

Auteurs : T. Lebret, L. Salomon, P. Richaud, K. Fizazi, S. Gaillard, A. Benchikh El Fegoun
Référence : Prog Urol, 2010, 20, S72, suppl. S1




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Références



Boccon-Gibod L., Fournier G., Bottet P., Marechal J.M., Guiter J., Rischman P., et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma Eur Urol 1997 ;  32 : 391-395discussion 5-6.
Schroder F.H., Whelan P., de Reijke T.M., Kurth K.H., Pavone-Macaluso M., Mattelaer J., et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the “European Organization for Research and Treatment of Cancer” (EORTC) Protocol 30892 Eur Urol 2004 ;  45 : 457-464 [cross-ref]
Seidenfeld J., Samson D.J., Hasselblad V., Aronson N., Albertsen P.C., Bennett C.L., et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis Ann Intern Med 2000 ;  132 : 566-577 [cross-ref]
Samson D.J., Seidenfeld J., Schmitt B., Hasselblad V., Albertsen P.C., Bennett C.L., et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma Cancer 2002 ;  95 : 361-376 [cross-ref]
Mottet N.A.G.M., Loulidi S., Wolff J.M. Intermittent versus continuous maximal androgen blockade in metastatic (D2) prostate cancer patients A randomized trial. J Urol 2009 ;  181 : 233
Miller K., Lingnau A., Keilholz U., Witzsch U., Haider A., Wachter U., et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer J Clin Oncol 2007 ;  25 : 5015
Shaw G.L., Wilson P., Cuzick J., Prowse D.M., Goldenberg S.L., Spry N.A., et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients BJU Int 2007 ;  99 : 1056-1065 [cross-ref]
Swanson G., Thompson I., Basler J., Crawford E.D. Metastatic prostate cancer-does treatment of the primary tumor matter? J Urol 2006 ;  176 : 1292-1298 [cross-ref]
Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 2008 ;  26 : 242-245 [cross-ref]
Paul A.B., Love C., Chisholm G.D. The management of bilateral ureteric obstruction and renal failure in advanced prostate cancer Br J Urol 1994 ;  74 : 642-645 [cross-ref]
Dowling R.A., Carrasco C.H., Babaian R.J. Percutaneous urinary diversion in patients with hormone-refractory prostate cancer Urology 1991 ;  37 : 89-91 [cross-ref]
Arcangeli G., Giovinazzo G., Saracino B., D’Angelo L., Giannarelli D., Micheli A. Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration Int J Radiat Oncol Biol Phys 1998 ;  42 : 1119-1126 [cross-ref]
Maillefert J.F., Sibilia J., Michel F., Saussine C., Javier R.M., Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma J Urol 1999 ;  161 : 1219-1222 [cross-ref]
Casey R. Zoledronic acid reduces bone loss in men with prostate cancer receiving goserelin 12 Month results EAU Meeting Berlin :  (2007). 
Abstract 716.
Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 2004 ;  96 : 879-882 [cross-ref]
Fizazi K., Lipton A., Mariette X., Body J.J., Rahim Y., Gralow J.R., et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates J Clin Oncol 2009 ;  27 : 1564-1571 [cross-ref]
James N.D., Caty A., Borre M., Zonnenberg B.A., Beuzeboc P., Morris T., et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial Eur Urol 2009 ;  55 : 1112-1123 [cross-ref]
Cook A.M., Lau T.N., Tomlinson M.J., Vaidya M., Wakeley C.J., Goddard P. Magnetic resonance imaging of the whole spine in suspected malignant spinal cord compression: impact on management Clin Oncol (R Coll Radiol) 1998 ;  10 : 39-43 [cross-ref]
Laredo J.D., Lakhdari K., Bellaiche L., Hamze B., Janklewicz P., Tubiana J.M. Acute vertebral collapse: CT findings in benign and malignant nontraumatic cases Radiology 1995 ;  194 : 41-48 [cross-ref]
Patchell R.A., Tibbs P.A., Regine W.F., Payne R., Saris S., Kryscio R.J., et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial Lancet 2005 ;  366 : 643-648 [cross-ref]
Lebret T., Mejean A. Physiopathology, diagnosis and management of bone metastases from prostate cancer Prog Urol 2008 ;  18 : S349-S356






© 2010 
Elsevier Masson SAS. Tous droits réservés.